Mevlyq (Eribulin Mesylate)

Eribulin Mesylate is used in cancers that rely on rapid cell division and microtubule dynamics.

• Metastatic breast cancer: improves overall survival in patients previously treated with anthracycline and taxane therapies.
• Advanced liposarcoma: provides disease control in patients with unresectable or metastatic soft‑tissue sarcoma.

• Eribulin Mesylate binds to the plus ends of microtubules, preventing their elongation and thereby disrupting microtubule dynamics. This inhibition halts cells in the G2‑M phase of the cell cycle, leading to apoptosis of rapidly proliferating cancer cells without affecting normal resting cells.

Eribulin Mesylate may cause a range of adverse reactions.

Common Side Effects

• Neutropenia: reduced neutrophil count, increasing infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Alopecia: hair loss that may be temporary.
• Nausea: mild to moderate upset stomach.
• Peripheral neuropathy: tingling or numbness in extremities.
• Constipation: decreased bowel movements.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils, requiring urgent care.
• Severe infections: opportunistic bacterial or fungal infections.
• Pulmonary toxicity: breathing difficulties or interstitial lung disease.
• Cardiac dysfunction: reduced left‑ventricular ejection fraction.
• Hepatic enzyme elevation: significant increase in liver function tests.
• Severe hypersensitivity: anaphylactic reactions requiring immediate medical intervention.

When using Eribulin Mesylate, clinicians should observe several safety measures.

• Monitor blood counts: perform regular complete blood counts to detect neutropenia.
• Assess hepatic function: check liver enzymes before and during therapy.
• Evaluate peripheral neuropathy: discontinue or adjust dose if neuropathy worsens.
• Avoid in known hypersensitivity: do not administer to patients with documented allergic reactions to the drug.
• Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are lacking.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Eribulin Mesylate can interact with other medicines, influencing safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.
• P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations.
• Concurrent myelosuppressive agents: heightened risk of severe neutropenia.
• Live vaccines: immunosuppression may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., midazolam): may require dose adjustment.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters.
• CYP2C8 inhibitors (e.g., gemfibrozil): observe for increased toxicity.
• Diuretics: watch for electrolyte disturbances.
• Antihypertensives: blood pressure may fluctuate.